News

EFFECTOR Therapeutics drops IPO, taking the SPAC path with Locust Walk

June 14, 2021
eFFECTOR Therapeutics, a clinical stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero, opted out of an IPO to be aquired by Locust Walk Acquisition Corp., a Special Purpose Acquisition Company (SPAC). The deal, anticipated to close in the third quarter...

Alessa Therapeutics Announces IND Clearance to Collaborate with the National Cancer Institute

June 14, 2021
Alessa Therapeutics, Inc., a clinical-stage drug development company founded by University of California, San Francisco professor Dr. Pamela Munster, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in...

Thermo Fisher partners with UCSF for early biotech manufacturing

May 21, 2021
A multimillion-dollar deal between the University of California, San Francisco, and biotech tools giant Thermo Fisher Scientific Inc. will put cell therapies almost literally within reach of UCSF cancer patients, doctors and researchers, as well as companies pursuing one of the hottest areas cancer...

Soteria Launches with $42 Million in Series A Financing

May 17, 2021
Soteria Biotherapeutics, Inc. a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, today announced a $42 million Series A financing led by Roche Venture Fund and 5AM Ventures with...

Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies

May 04, 2021
Emerging from stealth mode with a pipeline of FDA and EMA Orphan Drug Designation candidates, Epygenix Therapeutics Inc. is poised to become the first biopharmaceutical company to commercialize epilepsy drugs discovered in zebrafish. Epygenix Therapeutics’ six lead drug candidates were identified...

Fortis Therapeutics, a UCSF Founded Startup, Closes $40 Million Series A Financing

March 29, 2021
Fortis Therapeutics, an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.  “PCF is pleased that the 2017 funding to UCSF for their research on CD46 has been leveraged by Fortis for a...

Immunai Acquires UCSF Startup Dropprint Genomics

March 26, 2021
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. The Dropprint team co-founders Meena Subramaniam, PhD, and Rachel Gate, PhD, have also joined the Machine Learning and Computational...

NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

March 19, 2021
NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million.  MORE

Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for New Prostate Cancer Therapy

March 18, 2021
Founded in 2018 and based on technology developed at the University of California San Francisco, Alessa Therapeutics is developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease. And have announced the enrollment of the first patient in the...

UCSF Technology Sings at San Francisco Opera

March 11, 2021
In a strange marriage of arts and science, The San Francisco Opera costume department teamed up with doctors from UCSF to create a mask that will allow the company's singers to safely rehearse together -- while greatly diminishing the chances of spreading COVID-19. WATCH

Pages